Apoptosis characterizes immunological failure of HIV infected patients

Control Engineering Practice

Volumn 17, Issue 7, 2009, Pages 798-804

  Mhawej, Marie José ^a   Brunet François, Cécile ^b,c   Fonteneau, Raphael ^d   Ernst, Damien ^d   Ferré, Virginie ^b,c   Stan, Guy Bart ^e   Raffi, François ^b,c   Moog, Claude H ^a  

^a INSTITUT DE RECHERCHE EN COMMUNICATIONS ET CYBERNÉTIQUE DE NANTES   (France)

^b NANTES UNIVERSITY HOSPITAL   (France)

^c UNIVERSITÉ DE NANTES   (France)

^d UNIVERSITY OF LIÈGE   (Belgium)

^e UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Apoptosis; Clinical trial; HIV; Identifiability; Non linear systems; Parameter estimation

Indexed keywords

APOPTOSIS; BLOOD TESTS; CLINICAL DATUM; CLINICAL TRIAL; EARLY DIAGNOSIS; HIGHLY ACTIVE ANTI-RETROVIRAL THERAPIES; HIV; HIV INFECTIONS; IDENTIFIABILITY; INDUCED APOPTOSIS; INFECTED PATIENTS; SYSTEM PARAMETER IDENTIFICATIONS; T-CELLS;

CELL DEATH; DYNAMICAL SYSTEMS; LINEAR SYSTEMS; METAL ANALYSIS; NONLINEAR SYSTEMS; PATIENT MONITORING;

PARAMETER ESTIMATION;

EID: 67349137050     PISSN: 09670661     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.conengprac.2009.01.001     Document Type: Article

References (42)

1. Adams B.M., Banks H.T., Kwon H.-D., and Tran H.T. Dynamic multidrug therapies for HIV: Optimal and STI approaches. Mathematical Biosciences and Engineering 1 2 (2004)
2. Ahr B., Robert-Hebmann V., Devaux C., and Biard-Piechaczyk M. Apoptosis of uninfected cells induced by HIV envelope glycoproteins. Retrovirology 1 (2004)
3. Badley A.D. Cell death during HIV infection (2005), CRC Press, Boca Raton, FL. http://www.vonl.com/chips/cellhiv.htm 〈http://www.vonl.com/chips/cellhiv.htm〉
4. TM and the Versant HIV RNA 3.0 assays for quantitation of HIV-1 RNA in plasma samples. Journal of Clinical Virology 33 (2005) 43-51
5. Chang, H., & Astolfi, A. (2007). Immune response's enhancement via controlled drug scheduling. In 46th IEEE conference on decision and control, December, New Orleans, LA, USA.
6. Delfraissy, J. F. (2005). Monitoring of HIV infected patients: experts recommendations, Flammarion edition, Médecine Science, Paris. Available at 〈www.ladocumentationfrancaise.fr/brp/notices/044000467.shtml〉, (in French).
7. Estaquier J., et al. Programmed cell death and AIDS: Significance of T-cell apoptosis in pathogenic and nonpathogenic primate lentiviral infections. Proceedings of the National Academic of Sciences of the United States of America 91 (1994) 9431-9435
8. Fiches Techniques de la Firme Roche (2003). Available at 〈http://www.roche-diagnostics.fr〉.
9. Filter, R. A., & Xia, X. (2003). A penalty function to HIV/AIDS model parameter estimation. In 13th IFAC Symposium on System Identification, Rotterdam.
10. ® 1.5 assays on 1000 clinical specimens. Journal of Clinical Virology 34 (2005) 245-252
11. Gougeon M.-L., and Montagnier L. Programmed cell death as a mechanism of CD4 and CD8 T cell depletion in AIDS: Molecular control and effect of highly active anti-retroviral therapy. Annals of the New York Academy of Sciences 887 1 (1999) 199-212. http://www.blackwell-synergy.com/doi/abs/10.1111/j.1749-6632.1999.tb0793 4.x 〈http://www.blackwell-synergy.com/doi/abs/10.1111/j.1749-6632.1999. tb07934.x〉
12. Heffernan J.M., and Wahl L.M. Treatment interruptions and resistance: A review. In: Tan W.-Y., and Wu H. (Eds). Deterministic and stochastic models for AIDS epidemics and HIV infection with interventions (2005), World Scientific, Hackensack, NJ 425-455
13. Herbein G., Mahlknecht U., Batliwalla F., Gregersen P., Pappas T., Butler J., et al. Apoptosis of CD 8 + T cells is mediated by macrophages through interaction of HIV gp120 with chemokine receptor CXCR4. Nature 395 6698 (1998) 189-194. http://dx.doi.org/10.1038/26026 〈http://dx.doi.org/10.1038/26026〉
14. Ho D.D., et al. Rapid turnover of plasma virion and CD4 lymphocytes in HIV-1 infection. Nature 373 (1995) 123-126
15. ® HIV-1 RNA 3.0 (bDNA) assay quantification of HIV-1 RNA viral load in breast milk. Journal of Clinical Virology 34 (2005) 253-256
16. Khalili S., and Armaou A. Sensitivity analysis of HIV infection response to treatment via stochastic modeling. Chemical Engineering Science 63 (2008) 1330-1340
17. Moog C.H., Ouattara D.A., and Mhawej M.J. Analysis of the HIV dynamics. Proceedings of the seventh IFAC symposium on nonlinear control systems, Pretoria, South Africa, August 22-24 (2007)
18. Nowak M.A., and May R.M. Virus dynamics: Mathematical principles of immunology and virology (2002), Oxford University Press, Oxford
19. Ouattara, D. A. (2005). Mathematical analysis of the HIV-1 infection: Parameter estimation, therapies effectiveness, and therapeutical failures. In 27th annual international conference of the IEEE engineering in medicine and biology society, September, Shanghai, China.
20. Ouattara, D. A. (2006). Modeling of the HIV infection, identification and aid for the diagnosis. Ph.D. thesis, Ecole Centrale de Nantes & Université de Nantes, Nantes, France, (in French).
21. Ouattara, D. A., Mhawej, M.-J., & Moog, C. H. (2007). IRCCyN Web software for the computation of HIV infection parameters. Available at 〈http://www.hiv.irccyn.ec-nantes.fr〉.
22. Ouattara, D. A., Mhawej, M. J., & Moog, C. (2008). Clinical tests of therapeutical failures based on mathematical modeling of the HIV infection, Joint special issue of IEEE transactions on circuits and systems and IEEE transactions on Automatic Control, Special issue on systems biology, January, 230-241.
23. Ouattara, D. A., & Moog, C. H. (2007). Modelling of the HIV/AIDS infection : An aid for an early diagnosis of patients, Biology and control theory: Current challenges. In Lecture notes in control and information sciences (LNCIS), Springer, Berlin.
24. Pantaleo G., and Fauci A.S. Apoptosis in HIV infection. Nature Medicine 1 2 (1995) 118-120. http://dx.doi.org/10.1038/nm0295-118 〈http://dx.doi.org/10.1038/nm0295-118〉
25. Perelson A.S., and Nelson P.W. Mathematical analysis of HIV-1 dynamics in vivo. SIAM Review 41 1 (1999) 3-44
26. Perelson A.S., et al. Decay characteristics of HIV-1 infected compartment during combination therapy. Nature 387 (1997) 188-191
27. Prud'homme I.T., et al. Amplicor HIV Monitor, NASBA HIV-1 RNA QT and Quantiplex HIV RNA version 2.0 viral load assays: A Canadian evaluation. Journal of Clinical Virology 11 (1998) 189-202
28. Smith R.J. Adherence to antiretroviral HIV drugs: How many doses can you miss before resistance emerges?. Proceedings of the Royal Society B 273 (2006) 617-624
29. Smith R.J., and Wahl M. Distinct effects of protease and reverse transcriptase inhibition in an immunological model of HIV-1 infection with impulsive drug effects. Bulletin of Mathematical Biology 66 (2004) 1259-1283
30. Stan G.B., Belmudes F., Fonteneau R., Zeggwagh F., Lefebvre M.A., Michelet C., et al. Modelling the influence of activation-induced apoptosis of CD 4 + and CD 8 + T-cells on the immune system response of a HIV infected patient. IET Systems Biology 2 2 (2008) 94-102
31. Stewart S.A., Poon B., Song J.Y., and Chen I.S.Y. Human immunodeficiency virus Type 1 Vpr induces apoptosis through caspase activation. The Journal of Virology 74 (2000) 3105-3111
32. Tan W.Y., and Wu H. Deterministic and stochastic models for AIDS epidemics and HIV infection with interventions (2005), World Scientific, Singapore
33. U.S. Department of Health and Human Services, (2006). Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents, May. Available at 〈http://www.aidsinfo.nih.gov/guidelines〉.
34. Vassena, L., Proschan, M., Fauci, A. S., & Lusso, P. (2007). Interleukin 7 reduces the level of spontaneous apoptosis in CD 4 + and CD 8 + T cells from HIV-1 infected individuals. Proceedings of the National Academy of Sciences of the United States of America 2355-2360.
35. Wang J., Guan E., Roderiquez G., and Norcross M.A. Synergistic induction of apoptosis in primary CD 4 + T cells by macrophage-tropic HIV-1 and TGF-beta1. The Journal of Immunology 167 (2001) 3360-3366
36. Wei X., et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373 (1995) 117-122
37. Wodarz D., and Nowak M. Specific therapy regimes could lead to long term immunological control of HIV. Proceedings of the National Academy of Sciences of the United States of America (PNAS) 96 25 (1999) 14464-14469
38. Xia X., and Moog C.H. Identifiability of nonlinear systems with application to HIV/AIDS models. IEEE Transactions on Automatic Control 48 2 (2003) 330-336
39. Yun Yue F., Kovacs C., Dimayuga R., Xiao J.G., Parks P., Kaul R., et al. Preferential apoptosis of HIV-1 Specific CD 4 + T cells. The Journal of Immunology 174 (2005) 2196-2204
40. Zauli G., Gibellini D., Secchiero P., Dutartre H., Olive D., Capitani S., et al. Human immunodeficiency virus type 1 Nef protein sensitizes CD 4 + T lymphoid cells to apoptosis via functional upregulation of the CD95/CD95 ligand pathway. Blood 93 (1999) 1000-1010
41. Zurakowski, R., & Teel, R. A (2006). A model predictive control based scheduling method for HIV therapy. Journal of Theoretical Biology, July, 368-382.
42. Zurakowski, R., & Wodarz, D. (2007). Treatment interruptions to decrease risk of resistance emerging during therapy switching in HIV treatment, 46th IEEE conference on decision and control, December, New Orleans, LA, USA.